The Preparation of a Preclinical Dossier to Support an Investigational New Drug (IND) Application and First-in-Human Clinical Trial

A Comprehensive Guide to Toxicology in Preclinical Drug Development

Volumn , Issue , 2013, Pages 309-334

  Nugent, Paul ^a   Duncan, J Neil ^a   Colagiovanni, Dorothy B ^b  

^a PFIZER INC   (United States)

^b N30 Pharmaceuticals LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84883905705     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387815-1.00012-5     Document Type: Chapter

References (38)

1. Kuhnert B.R. ICH at 20: An Overview. Global Forum 2011, 3:17-18.
2. Juillet Y. The CTD: A tool for global development and assessment. Global Forum 2011, 3:25-26.
3. Finkle C.D., Atkins J. Project management and international regulatory requirements and strategies for First-in-Human trials. Strategies and Routes to First-in-Human Trial 2010, 513-541. Wiley, Hoboken, NJ, Early Drug Development. M.N. Cayen (Ed.).
4. Sommer M.R., Ammann M., Hillgren U.B., Kovacs K.K., Wilner K. First-in-Human regulatory submissions. Strategies and Routes to First-in-Human Trials 2010, 543-593. Wiley & Sons, Inc, Hoboken, NJ, Early Drug Development. M.N. Cayen (Ed.).
5. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Safety-M4S(R2) - Nonclinical Overview and Nonclinical Summaries of Module 2 2002, Organisation of Module 4, Geneva, Switzerland.
6. European Commission Revision 2. Detailed guidance for the request for authorization of a clinical trial on a medicinal product for human use to the competent authorities, notification of substantial amendments and declaration of the end of the trial 2005, Enterprise Directorate General, Brussels, Belgium.
7. European Commission Draft Revision 3. Detailed guidance for the request for authorization of a clinical trial on a medicinal product for human use to the competent authorities, notification of substantial amendments and declaration of the end of the trial 2009, Enterprise Directorate General, Brussels, Belgium.
8. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals M3(R2) 2010, Geneva, Switzerland.
9. Wang T., Jacobson-Kram D., Pilaro A.M., Lapadula D., Jacobs A., Brown P., et al. ICH Guidelines: Inception, Revision, and Implications for Drug Development. Tox Sci 2010, 118:356-367.
10. Food and Drug Administration, CDER Division Guidance for Industry M4: Organization of the CTD 2001, DC. Government Printing Office, Washington.
11. Food and Drug Administration, CDER Division Guidance for Industry: Single Dose Acute Toxicity for Pharmaceuticals 1996, DC. Government Printing Office, Washington.
12. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Guideline on Strategies to Identify and Mitigate Risks for First-in-Human Clinical Trials with Investigational Medicinal Products 2007, London, England.
13. Milton M.N., Horvath C.J. The EMEA guideline on First-in-Human clinical trials and its impact on pharmaceutical development. Toxicol Pathol 2009, 37:363-371.
14. Buckley L.A., Chapman K., Burns-Naas L.A., Todd M.D., Martin P.L., Lansita J.A. Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals. Int J Tox 2011, 30:583-590.
15. DeGeorge J.J., Ahn C.-H., Andrews P.A., Brower M.E., Giogio D.W., Goheer M.A., et al. Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother Pharmacol 1998, 41:173-185.
16. Ponce R. ICH S9: developing anticancer drugs, one year later. Tox Path 2011, 39:913-915.
17. Muller P.Y. Comparative requirements for exploratory clinical trials - eIND, eCTA, and microdosing. Adv Drug Delivery Reviews 2011, 63:511-517.
18. Black H.E., Montgomery S.B., Moch R.W. Toxicology program to support initiation of a clinical Phase I program for a new medicine. Strategies and Routes to First-in-Human Trial 2010, 283-307. Wiley & Sons, Inc, Hoboken, NJ, Early Drug Development. M.N. Cayen (Ed.).
19. Preclinical Safety Evaluation of Biopharmaceuticals. Wiley. Hoboken, NJ 2008, J.A. Cavagnaro (Ed.).
20. Benbow J.W., Aubrecht J., Banker M.J., Nettleton D., Aleo M.D. Predicting safety toleration of pharmaceutical chemical leads: cytotoxicity correlations to exploratory toxicity studies. Tox Letts 2011, 197:175-182.
21. Gad S.C., Cassidy C.D., Aubert N., Spainhour B., Robbe H. Nonclinical vehicle use in studies by multiple routes in multiple species. Int J Toxicology 2006, 25:499-521.
22. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use S2(R1) 2011, Geneva, Swizterland.
23. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline Safety Pharmacology Studies for Human Pharmaceuticals 2000, S7A. Geneva, CPMP/ICH/539/00-ICH S7A, Geneva, Switzerland.
24. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline The Nonclinical Evaluation of the Potential for Safety Pharmacology Studies for Delayed Ventricular Repolarization (QT Interval Polarization) by Human Pharmaceuticals S7B 2005, Geneva, Switzerland.
25. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals 2011, 1997 and Addendum, S6(R1). Geneva, Switzerland.
26. Irwin S. Comprehensive observational assessment: IaA systematic, quantitative procedure for assessing the behavioral and physiological state of the mouse. Psychopharmacologia 1968, 13:222-257. Berl.
27. Moser V.C. Screening Approaches to Neurotoxicity: A Functional Observational Battery. Int J Toxic 1989, 8:85-93.
28. Moser V.C. Functional Assays for Neurotoxicity Testing. Toxicol Pathol 2011, 39:36-45.
29. Pellegatti M., Pagliarusco S., Solazzo L., Colato D. Plasma protein binding and blood-free concentrations: which studies are needed to develop a drug?. Expert Opin Drug Metatab Toxicol 2011, 7:1009-1020.
30. Baillie T.A., Cayen M.N., Fouda H., Gerson R.J., Green J.D., Grossman S.J., et al. Contemporary issues in toxicology: drug metabolites in safety testing. Toxicol Appl Pharmacol 2002, 182:188-196.
31. Food and Drug Administration, CDER Division Testing of Drug Metabolites 2008, DC. Government Printing Office, Washington.
32. Walker D., Brady J.T., Dalvie D., Davis J.W., Dowty M., Duncan J.N., et al. A holistic strategy for characterizing the safety of metabolites through drug discovery and development. Chem Res Toxicol 2002, 22:1653-1662.
33. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline Immunotoxicity Studies for Human Pharmaceuticals 2006, S8 Geneva, Switzerland.
34. Bugelski P.J., Treacy G. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr Opin Mol Ther 2004, 6:10-16.
35. Ponce R., Abad L., Amaravadi L., Gelzleichter T., Gore E., Green J., et al. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol 2009, 54:164-182.
36. Food and Drug Administration Estimating the Maximum Safe Starting Doses in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers 2005, DC. Government Printing Office, Washington.
37. Muller P.Y., Milton M., Lloyd P., Sims J., Brennan F.R. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. Current Opini Biotech Dec 2009, 20(6):722-729.
38. Suntharalingam G., Perry R., Ward S., Brett S.J., Castello-Cortes A., Brunner M.D., et al. Cytokine storm in Phase I trial of the anti-CD28 monoclonal antibody. N Engl J Med 2006, 355:1018-1028.